For the quarter ended November 2025, Neogen (NEOG) reported revenue of $224.69 million, down 2.8% over the same period last year. EPS came in at $0.10, compared to $0.11 in the year-ago quarter.
The reported revenue represents a surprise of +7.13% over the Zacks Consensus Estimate of $209.74 million. With the consensus EPS estimate being $0.07, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Animal Safety: $59.14 million compared to the $56.56 million average estimate based on three analysts. The reported number represents a change of -11.8% year over year.
- Revenues- Food Safety: $165.55 million versus the three-analyst average estimate of $153.19 million. The reported number represents a year-over-year change of +0.8%.
- Revenues- Food Safety- Indicator Testing, Culture Media & Other: $86.11 million versus $76.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
- Revenues- Animal Safety- Life Sciences: $1.45 million versus $1.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -11% change.
- Revenues- Animal Safety- Veterinary Instruments & Disposables: $13.68 million compared to the $15.68 million average estimate based on two analysts. The reported number represents a change of -20.8% year over year.
- Revenues- Animal Safety- Animal Care & Other: $8.89 million versus the two-analyst average estimate of $10.41 million. The reported number represents a year-over-year change of -9%.
- Revenues- Food Safety- Natural Toxins & Allergens: $20.44 million versus the two-analyst average estimate of $19.1 million. The reported number represents a year-over-year change of -0.3%.
- Revenues- Animal Safety- Genomics Services: $17.18 million compared to the $4.83 million average estimate based on two analysts.
- Revenues- Food Safety- Genomics Services: $6.26 million versus the two-analyst average estimate of $13.93 million.
- Revenues- Food Safety- Biosecurity Products: $4.57 million compared to the $8.74 million average estimate based on two analysts.
- Revenues- Food Safety- Bacterial & General Sanitation: $44.92 million versus $39.28 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
- Revenues- Animal Safety- Biosecurity Products: $17.93 million versus $18.7 million estimated by two analysts on average.
View all Key Company Metrics for Neogen here>>>
Shares of Neogen have returned +5.7% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Neogen Corporation (NEOG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
